Rigel Pharmaceuticals (RIGL) capped FY 2025 with Q4 total revenue of US$69.8 million and basic EPS of US$14.72, while trailing twelve month figures show revenue of US$294.3 million and EPS of US$20.40, all tied to net income excluding extra items of US$367.0 million. Over the past few reported quarters, revenue has ranged from US$53.3 million to US$101.7 million and quarterly EPS has moved from US$0.64 to US$14.72. This sets up a year in which trailing earnings growth was very large and net margins moved into clearly positive territory. In that context, investors are likely to focus on how durable these margins look and what they imply for the quality of Rigel's profitability.

See our full analysis for Rigel Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely held narratives around Rigel, and where the latest figures challenge or reinforce those views.

1999% EPS jump built on non cash items

• Over the last 12 months, basic EPS moved from under US$1 to US$20.40, while trailing net income excluding extra items reached US$367.0 million on US$294.3 million of revenue, a very large step up that also comes with a 9.8% net margin.
• What stands out for the bullish narrative is that this surge is described as containing a high level of non cash earnings, yet bulls still lean on themes like strong cash generation and disciplined cost control. That can be hard to reconcile when a large share of the recent US$367.0 million of profit is not tied to cash movements.
  • Bulls point to operational leverage and pipeline funding capacity, while the data reminds you that non cash collaboration revenue played a big role in FY 2025.
  • That tension is important if you are trying to judge how much of the US$20.40 EPS is repeatable through the commercial portfolio versus one time items.

Have a look at how bullish investors connect these numbers to their long term case for Rigel: 🐂 Rigel Pharmaceuticals Bull Case

Revenue growth trails market at 6.3%

• Rigel’s trailing revenue growth rate of 6.3% per year sits below the 10.2% per year figure given for the broader US market, even though quarterly revenue in FY 2025 ranged from US$53.3 million to US$101.7 million and reached US$294.3 million on a trailing basis.
• Bears argue that one time benefits and a narrow product set mean this 6.3% growth rate could prove fragile, and the numbers give them some talking points.
  • The risk section highlights that forecasts point to an average 33.2% annual earnings decline over the next three years, which sits uncomfortably next to the modest revenue growth rate.
  • On top of that, reliance on three main commercial products and collaboration income means any slowdown in those streams would quickly show up in revenue, given the gap to the broader US market growth rate.

Skeptical views lean heavily on these growth and concentration concerns, and you can see their full case here: 🐻 Rigel Pharmaceuticals Bear Case

Low 1.5x P/E versus DCF fair value

• The shares trade on a trailing P/E of 1.5x based on the recent earnings, with a current price of US$29.63 compared with a DCF fair value of about US$72.95, which implies a large gap between price and that model based estimate.
• Consensus narrative writers see this gap as a key part of the risk reward trade off, because the same data set that gives a low P/E and high DCF fair value also includes analyst expectations for earnings to decline by about 33.2% per year over the next three years.
  • On one side, you have multi year profit growth and trailing net income of US$367.0 million supporting the low multiple and DCF fair value of US$72.95.
  • On the other, the expectation of shrinking margins from 36.5% today to mid teens in several years suggests that the current earnings level may not be a simple guide to future profitability.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Rigel Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With such mixed signals across earnings quality, revenue growth and valuation, it helps to look at the full picture yourself and move quickly from headline impressions to your own view. To see how the current data balances both concerns and potential upside for Rigel, take a close look at the 3 key rewards and 2 important warning signs.

See What Else Is Out There

Rigel’s story leans on very large non cash earnings, modest 6.3% revenue growth and expectations for a 33.2% annual earnings decline. Together, these factors raise questions about the durability of its performance.

If concentration risk and earnings uncertainty bother you, take a few minutes to review 74 resilient stocks with low risk scores that aim to prioritise resilience and a smoother ride for your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.